A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec
- Registration Number
- NCT05352815
- Lead Sponsor
- Novo Nordisk A/S
- Brief Summary
This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to insulin icodec taken once a week in people with type 2 diabetes.
The study will look at how well IcoSema controls blood sugar level in people with type 2 diabetes compared to insulin icodec.
Participants will either get IcoSema or insulin icodec. Which treatment participants get is decided by chance. IcoSema and insulin icodec are both new medicines that doctors cannot prescribe.
Participants will get IcoSema or insulin icodec, which participants must inject once a week with a pen, which has a small needle, in a skin fold in the thigh, upper arm, or stomach.
The study will last for about 1 year and 1 month. Participants will have 21 clinic visits, 31 phone/video calls with the study doctor, and 4 contacts with the site that can either be clinic visits or phone/video calls At 11 clinic visits participants will have blood samples taken. At 7 clinic visits participants cannot eat or drink (except for water) for 8 hours before the visit.
Women cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period.
Not applicable for China: Participants will be asked to wear a sensor that measures their blood sugar level all the time during a 5 week period at the end of the study.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1291
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description IcoSema IcoSema - Insulin icodec Insulin icodec -
- Primary Outcome Measures
Name Time Method Change in Glycated Haemoglobin (HbA1c) Baseline (Week 0), Week 52 Change from baseline (week 0) to week 52 in HbA1c is presented. The outcome measure was evaluated based on the data from in study period, where all data from randomisation until last date of any of the following: 1) last direct participant-site contact; 2) participants who withdrew their informed consent; 3) last participant-investigator contact as defined by the investigator for participants who lost to follow-up (i.e. possibly an unscheduled phone visit); 4) death of participants who died before any of the above.
- Secondary Outcome Measures
Name Time Method Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (Less Than 3.0 Millimoles Per Litre [mmol/L] (54 Milligram Per Decilitre [mg/dL]), Confirmed by Blood Glucose [BG] Meter) or Severe Hypoglycaemic Episodes (Level 3) From baseline week 0 to week 57 Hypoglycaemic episodes were classified according to the American Diabetes Association/ International Hypoglycaemia Study Group, where glycemic criteria for level 2 was less than (\<) 3.0 mmol/L (54 mg/dL) and level 3 had no specific glucose threshold. The outcome measure was evaluated based on data from on treatment period, where all data from date of first dose of randomised treatment as recorded on the electronic case report form (eCRF) until the first date of any of the following: 1) last follow-up visit ; 2) last date on randomised treatment +6 weeks (corresponding to 5 weeks after the end of the dosing interval for both treatment arms); 3) end-date for the in-study data points sets.
Change in Body Weight Baseline (Week 0), Week 52 Change from baseline (week 0) to week 52 in body weight is presented. The outcome measure was evaluated based on the data from in study period, where all data from randomisation until last date of any of the following: 1) last direct participant-site contact; 2) participants who withdrew their informed consent; 3) last participant-investigator contact as defined by the investigator for participants who lost to follow-up (i.e. possibly an unscheduled phone visit); 4) death of participants who died before any of the above.
Percentage of Time in Range 3.9-10.0 mmol/L (70-180 mg/dL) Using Continuous Glucose Monitoring (CGM) System, Dexcom G6 From week 48 to week 52 Time in range was defined as 100 times the number of recorded measurements in glycemic range 3.9-10.0 mmol/L (70-180 mg/dL), both inclusive, divided by the total number of recorded measurements. The outcome measure was evaluated based on the data from in study period: Data from randomisation until last date of any of the following: 1) the last direct participant-site contact; 2) withdrawal for participants who withdraw their informed consent; 3) the last participant-investigator contact as defined by the investigator for participants who are lost to follow-up (i.e. possibly an unscheduled phone visit); 4) death for participants who die before any of the above.
Percentage of Time Spent < 3.0 mmol/L (54 mg/dL) Using Continuous Glucose Monitoring (CGM) System, Dexcom G6 From week 48 to week 52 Time spent below threshold was defined as 100 times the number of recorded measurements below the threshold, divided by the total number of recorded measurements. The outcome measure was evaluated based on the data from in study period: Data from randomisation until last date of any of the following: 1) the last direct participant-site contact; 2) withdrawal for participants who withdraw their informed consent; 3) the last participant-investigator contact as defined by the investigator for participants who are lost to follow-up (i.e. possibly an unscheduled phone visit); 4) death for participants who die before any of the above.
Percentage of Time Spent > 10.0 mmol/L (180 mg/dL) Using Continuous Glucose Monitoring (CGM) System, Dexcom G6 From week 48 to week 52 Time spent above threshold is defined as 100 times the number of recorded measurements above the threshold, divided by the total number of recorded measurements. The outcome measure was evaluated based on the data from in study period: Data from randomisation until last date of any of the following: 1) the last direct participant-site contact; 2) withdrawal for participants who withdraw their informed consent; 3) the last participant-investigator contact as defined by the investigator for participants who are lost to follow-up (i.e. possibly an unscheduled phone visit); 4) death for participants who die before any of the above.
Weekly Basal Insulin Dose From week 50 to week 52 Estimated mean average weekly basal insulin dose from week 50 to week 52 of treatment is presented. The outcome measure was evaluated based on data from on treatment period, where all data from date of first dose of randomised treatment as recorded on the electronic case report form (eCRF) until the first date of any of the following: 1) last follow-up visit (V56); 2) last date on randomised treatment +6 weeks (corresponding to 5 weeks after the end of the dosing interval for both treatment arms); 3) end-date for the in-study data points sets.
Change in Fasting Plasma Glucose (FPG) Baseline (Week 0), Week 52 Change in FPG from baseline (week 0) to week 52 is presented. The outcome measure was evaluated based on the data from in study period: Data from randomisation until last date of any of the following: 1) the last direct participant-site contact; 2) withdrawal for participants who withdraw their informed consent; 3) the last participant-investigator contact as defined by the investigator for participants who are lost to follow-up (i.e. possibly an unscheduled phone visit); 4) death for participants who die before any of the above.
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL), Confirmed by BG Meter) From baseline week 0 to week 57 Hypoglycaemic episodes were classified according to the American Diabetes Association/ International Hypoglycaemia Study Group, where glycemic criteria for level 2 was less than (\<) 3.0 mmol/L (54 mg/dL). The outcome measure was evaluated based on data from on treatment period, where all data from date of first dose of randomised treatment as recorded on the electronic case report form (eCRF) until the first date of any of the following: 1) last follow-up visit ; 2) last date on randomised treatment +6 weeks (corresponding to 5 weeks after the end of the dosing interval for both treatment arms); 3) end-date for the in-study data points sets.
Number of Severe Hypoglycaemic Episodes (Level 3) From baseline week 0 to week 57 Hypoglycaemic episodes were classified according to the American Diabetes Association/ International Hypoglycaemia Study Group, where glycemic criteria for level 3 had no specific glucose threshold. The outcome measure was evaluated based on data from on treatment period, where all data from date of first dose of randomised treatment as recorded on the electronic case report form (eCRF) until the first date of any of the following: 1) last follow-up visit; 2) last date on randomised treatment +6 weeks (corresponding to 5 weeks after the end of the dosing interval for both treatment arms); 3) end-date for the in-study data points sets.
Trial Locations
- Locations (208)
Endeavor Health
🇺🇸Skokie, Illinois, United States
Unidade Local De Saude Da Regiao De Aveiro E.P.E.
🇵🇹Aveiro, Portugal
St. Olavs Hospital HF
🇳🇴Trondheim, Norway
NZOZ Przychodnia Specjalistyczna Medica
🇵🇱Lublin, Lubelski, Poland
Uniwersyteckie Centrum Kliniczne (UCK)
🇵🇱Gdansk, Poland
NZOZ "CenterMed Lublin" Sp. z o.o.
🇵🇱Lublin, Poland
Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych I Administracji
🇵🇱Warszawa, Poland
Hospital de Braga
🇵🇹Braga, Portugal
Centro Hospitalar Lisboa Ocidental
🇵🇹Lisboa, Portugal
Unidade Local de Saúde de Matosinhos
🇵🇹Matosinhos, Portugal
Advanced Clinical Research LLC
🇵🇷Bayamon, Puerto Rico
Manati Ctr For Clin Research
🇵🇷Manati, Puerto Rico
Institutul National De Diabet Nutritie Si Boli Metabolice Prof.Dr.N.Paulescu Bucuresti- Ion Movila
🇷🇴Bucharest, Bucurestii, Romania
CMI Diabet, Nutritie, Boli Metabolice "Dr Pop Lavinia"
🇷🇴Baia Mare, Maramures, Romania
Mariodiab Clinic SRL
🇷🇴Brasov, Romania
SC Consultmed SRL
🇷🇴Iasi, Romania
Clinica Korall S.R.L. Satu Mare
🇷🇴Satu-Mare, Romania
Tumen State Medical University
🇷🇺Tumen, Russia, Russian Federation
Arkhangelsk Regional Clinical Hospital
🇷🇺Arkhangelsk, Russian Federation
Sverdlovsk Regional Clinical Hospital #1
🇷🇺Ekaterinburg, Russian Federation
Irkutsk State Medical Academy of Postgraduate Education
🇷🇺Irkutsk, Russian Federation
Limited Liability Company "AriVa-Med"
🇷🇺Kursk, Russian Federation
City Consultative & Diagnostic Centre #1
🇷🇺Saint-Petersburg, Russian Federation
Saratov regional clinical hospital
🇷🇺Saratov, Russian Federation
Endocrinology, Diabetes and Metabolism Diseases Clinic
🇷🇸Belgrade, Serbia
Deepak Lakha
🇿🇦Johannesburg, Gauteng, South Africa
Hemant Makan
🇿🇦Johannesburg, Gauteng, South Africa
Wits Bara Clinical Trial Site
🇿🇦Johannesburg, Gauteng, South Africa
Dr Pillay's Rooms
🇿🇦Durban, KwaZulu-Natal, South Africa
Armansis Medical Centre
🇿🇦Brits, North West, South Africa
Langeberg Clinical Trials
🇿🇦Cape Town, Western Cape, South Africa
Netcare Alberton Hospital
🇿🇦Alberton, South Africa
Changhua Christian Hospital
🇨🇳Changhua City, Taiwan
Pri Med Grp dba/Gil Ctr Fam
🇺🇸Gilbert, Arizona, United States
Medical Investigations, Inc.
🇺🇸Little Rock, Arkansas, United States
Headlands Research California, LLC
🇺🇸Escondido, California, United States
Downtown LA Res Ctr. Inc.
🇺🇸Los Angeles, California, United States
NorCal Endocrinology and Internal Medicine
🇺🇸San Ramon, California, United States
Northeast Research Institute
🇺🇸Fleming Island, Florida, United States
Iowa Diab & Endo Res Center
🇺🇸West Des Moines, Iowa, United States
Kunisaki Makoto Clinic
🇯🇵Fukuoka-shi, Fukuoka, Japan
Yoshimura clinic
🇯🇵Kumamoto, Japan
Hisatomi Clinic
🇯🇵Saga-shi, Saga, Japan
Clínicos Asociados BOCM, S.C.
🇲🇽Mexico City, Mexico
Nordlandssykehuset Bodø
🇳🇴Bodø, Norway
Drammen sykehus - Vestre Viken HF
🇳🇴Drammen, Norway
Sykehuset Innlandet HF Hamar
🇳🇴Hamar, Norway
Oslo universitetssykehus Aker
🇳🇴Oslo, Norway
Methodist Phys. Clinic
🇺🇸Omaha, Nebraska, United States
Momentum Clinical Research Darlinghurst
🇦🇺Darlinghurst, New South Wales, Australia
The Second Affiliated Hospital of Nanjing Medical University-Endocrinology
🇨🇳Nanjing, Jiangsu, China
Unidade Local De Saude De Almada-Seixal E.P.E.
🇵🇹Almada, Portugal
Velocity Clin Res Wstlke
🇺🇸Los Angeles, California, United States
Javara/Privia Med Grp GA,LLC
🇺🇸Albany, Georgia, United States
Pacific Clinical Studies
🇺🇸Los Alamitos, California, United States
Diablo Clinical Research, Inc.
🇺🇸Walnut Creek, California, United States
Creekside Endocrine Associates, PC
🇺🇸Denver, Colorado, United States
Clinical Res Of W Florida Inc
🇺🇸Clearwater, Florida, United States
Metabolic Research Institute Inc
🇺🇸West Palm Beach, Florida, United States
Physicians Research Assoc. LLC
🇺🇸Lawrenceville, Georgia, United States
The Affiliated Hospital of Jiangsu University-Endocrinology
🇨🇳Zhenjiang, Jiangsu, China
Texas Diabetes &Endocrinology
🇺🇸Round Rock, Texas, United States
Peking University People's Hospital-Endocrinology
🇨🇳Beijing, Beijing, China
Harrison International Peace Hospital-Endocrinology
🇨🇳Hengshui, Hebei, China
Huaihe Hospital of Henan University-Endocrinology
🇨🇳Kaifeng, Henan, China
Sasaki Internal Medicine
🇯🇵Hokkaido, Japan
Unidade Local De Saude De Matosinhos E.P.E.
🇵🇹Senhora Da Hora, Matosinhos, Matosinhos, Portugal
UZ Brussel - Universitair Ziekenhuis Brussel
🇧🇪Brussel, Belgium
Anhui Provincial Hospital-Endocrinology
🇨🇳Hefei, Anhui, China
Huizhou Central People's Hospital-Endocrinology
🇨🇳Huizhou, Guangdong, China
Shanghai Fifth People's Hospital-Endocrinology
🇨🇳Shanghai, Shanghai, China
General Hospital of Tianjin Medical University-Endocrinology
🇨🇳Tianjin, Tianjin, China
Hospital Da Luz S.A.
🇵🇹Lisboa, Portugal
Spitalul Judetean De Urgenta Sfantul Ioan Cel Nou Suceava
🇷🇴Suceava, Romania
Scripps Whittier Diabetes Inst
🇺🇸La Jolla, California, United States
Torrance Clin Res Inst, Inc.
🇺🇸Lomita, California, United States
The Second Affiliated Hospital of Soochow University-Endocrinology
🇨🇳Suzhou, Jiangsu, China
Hospital Luz Arrabida, S.A.
🇵🇹Vila Nova de Gaia, Portugal
John Muir Physicians Network
🇺🇸Concord, California, United States
Elite Research Center
🇺🇸Flint, Michigan, United States
Jefferson City Medical Group, PC
🇺🇸Jefferson City, Missouri, United States
The Research Group of Lexington LLC
🇺🇸Lexington, Kentucky, United States
Ileana J Tandron APMC
🇺🇸Slidell, Louisiana, United States
Northern Pines Hlth Ctr, PC
🇺🇸Buckley, Michigan, United States
Valley Clinical Trials, Inc.
🇺🇸Northridge, California, United States
Suncoast Clin Res Port Richey
🇺🇸New Port Richey, Florida, United States
Javara Inc.
🇺🇸Fayetteville, Georgia, United States
International Diabetes Center
🇺🇸Minneapolis, Minnesota, United States
Palm Research Center Inc.
🇺🇸Las Vegas, Nevada, United States
Cotton O'Neil Clin Research Ctr
🇺🇸Topeka, Kansas, United States
New Orleans Center for Clinical Research
🇺🇸New Orleans, Louisiana, United States
MedStar Hlth Res Institute
🇺🇸Hyattsville, Maryland, United States
Brigham & Women's Hospital
🇺🇸Boston, Massachusetts, United States
PharmQuest Life Sciences LLC
🇺🇸Greensboro, North Carolina, United States
AM Diabetes And Endocrinology Center
🇺🇸Bartlett, Tennessee, United States
University of NE Med Ctr
🇺🇸Omaha, Nebraska, United States
Central Ohio Clinical Research LLC
🇺🇸Columbus, Ohio, United States
New Venture Medical Research
🇺🇸Wadsworth, Ohio, United States
Southgate Medical Group, LLP
🇺🇸West Seneca, New York, United States
Southern New Hampshire Diabete
🇺🇸Nashua, New Hampshire, United States
Albuquerque Clin Trials, Inc.
🇺🇸Albuquerque, New Mexico, United States
Holston Medical Group_Bristol
🇺🇸Bristol, Tennessee, United States
Mid Hudson Medical Research, PLLC
🇺🇸New Windsor, New York, United States
Javara Inc. / Privia Medical Group Gulf Coast PLLC
🇺🇸Houston, Texas, United States
Velocity Clinical Res-Dallas
🇺🇸Dallas, Texas, United States
Univ of TX SW Med Ctr Dallas
🇺🇸Dallas, Texas, United States
Sun Research Institute
🇺🇸San Antonio, Texas, United States
Texas Diabetes & Endocrinology, P.A._Austin
🇺🇸Austin, Texas, United States
PrimeCare Medical Group
🇺🇸Houston, Texas, United States
DCOL Ctr for Clin Res
🇺🇸Longview, Texas, United States
Briggs Clinical Research, LLC
🇺🇸San Antonio, Texas, United States
Javara Inc/Privia Md GpLLC Fst
🇺🇸Forest, Virginia, United States
HealthStar Physicians PC
🇺🇸Morristown, Tennessee, United States
Protenium Clinical Research
🇺🇸Hurst, Texas, United States
Andres Garcia-Zuniga, MD, P.A
🇺🇸Laredo, Texas, United States
Milton Haber, M.D.
🇺🇸Laredo, Texas, United States
Javara Inc Privia Grp Gulf Cst
🇺🇸San Marcos, Texas, United States
Holdsworth House Clinical Research
🇦🇺Darlinghurst, New South Wales, Australia
Amarillo Med Spec LLP
🇺🇸Amarillo, Texas, United States
Eastern Virginia Medical School
🇺🇸Norfolk, Virginia, United States
PlanIt Research, PLLC
🇺🇸Houston, Texas, United States
SimCare, PLLC
🇺🇸Sugar Land, Texas, United States
Amherst Family Practice P.C.
🇺🇸Winchester, Virginia, United States
Turku University Hospital
🇫🇮Turku, Finland
Ähtärin terveysasema
🇫🇮Ähtäri, Finland
Gujarat Endocrine Centre
🇮🇳Ahmedabad, Gujarat, India
Novatrials
🇦🇺Kotara, New South Wales, Australia
Illawarra Diabetes Service Clinical Trials & Research Unit
🇦🇺Wollongong, New South Wales, Australia
Royal Brisbane and Women's Hospital
🇦🇺Herston, Queensland, Australia
Southern Adelaide Diabetes & Endocrine Services
🇦🇺Oaklands Park, South Australia, Australia
Launceston General Hospital
🇦🇺Launceston, Tasmania, Australia
Barwon Health (The Geelong Hospital)
🇦🇺Geelong, Victoria, Australia
The Alfred Hospital
🇦🇺Melbourne, Victoria, Australia
Imeldaziekenhuis - Bonheiden - Department of Endocrinology
🇧🇪Bonheiden, Belgium
Cliniques Universitaires Saint-Luc - Serv Endocrinologie - Diabétologie
🇧🇪Bruxelles, Belgium
UZA - UZ Antwerpen - Department of Endocrinology
🇧🇪Edegem, Belgium
AZ Groeninge - Kortrijk - Centrum Endo - Diabetologie
🇧🇪Kortrijk, Belgium
UZ Leuven - Endocrinology
🇧🇪Leuven, Belgium
"IPSMC - d-r Nikolay Kostadinov" EOOD
🇧🇬Burgas, Bulgaria
DCC I- Pleven EOOD
🇧🇬Pleven, Bulgaria
Harrison International Peace Hospital
🇨🇳Hengshui, Hebei, China
Poliklinika Solmed
🇭🇷Zagreb, Grad Zagreb, Croatia
'Medical center Medi city 21' OOD
🇧🇬Kyustendil, Bulgaria
Jinan Central Hospital
🇨🇳Ji'nan, Shandong, China
Klinicki bolnicki centar Osijek
🇭🇷Osijek, Croatia
UMHAT "Kaspela", Depart. Endocrinology and Metab. Diseases
🇧🇬Plovdiv, Bulgaria
MMA-MHAT Sofia, Clinic of Endocrinology and Metab. Diseases
🇧🇬Sofia, Bulgaria
Changzhou No.2 People's Hospital, Yanghu Branch
🇨🇳Changzhou, Jiangsu, China
Health Step Finland Oy
🇫🇮Kuopio, Finland
Raision sosiaali- ja terveyskeskus
🇫🇮Raisio, Finland
Tampereen diabetesvastaanotto
🇫🇮Tampere, Finland
Chongqing University Three Gorges Hospital
🇨🇳ChongQing, Chongqing, China
Opca bolnica Pula
🇭🇷Pula, Croatia
The First People's Hospital of Changzhou
🇨🇳Changzhou, Jiangsu, China
The Second Affiliated Hospital of Nanjing Medical University_Nanjing
🇨🇳Nanjing, Jiangsu, China
The Second Hospital of Tianjin Medical University
🇨🇳Tianjin, Tianjin, China
Poliklinika SLAVONIJA OSIJEK
🇭🇷Osijek, Osječko - Baranjska Županija, Croatia
KBC Rijeka, Endokrinologija
🇭🇷Rijeka, Croatia
Government Medical College, Kozhikode
🇮🇳Kozhikode, Kerala, India
Jothydev's Diabetes & Research Center
🇮🇳Thriruvananthapuram, Kerala, India
TOTALL Diabetes Hormone Institute
🇮🇳Indore, Madhya Pradesh, India
Excel Endocrine Centre
🇮🇳Kolhapur, Maharashtra, India
Seth GS medical college and KEM Hospital
🇮🇳Mumbai, Maharashtra, India
Post Graduate Institute of Medical Education & Research
🇮🇳Chandigarh, Punjab, India
M.V.Hospital for Diabetes Pvt. Ltd.
🇮🇳Chennai, Tamil Nadu, India
Arthur Asirvatham hospital,
🇮🇳Madurai, Tamil Nadu, India
Osmania General Hospital
🇮🇳Hyderabad, Telangana, India
Ramdev Rao Hospital
🇮🇳Hyderabad, Telangana, India
Heiwadai Hospital
🇯🇵Miyazaki-shi, Miyazaki, Japan
Kumanomae Nishimura Internal Medical Clinic
🇯🇵Arakawa-ku, Tokyo, Japan
Akaicho Clinic
🇯🇵Chiba-shi, Chiba, Japan
Futata Tetsuhiro Clinic Meinohama
🇯🇵Fukuoka-shi, Fukuoka, Japan
Lady Hardinge Medical College
🇮🇳New Delhi, India
A.O.U. Consorziale Policlinico di Bari
🇮🇹Bari, BA, Italy
Policlinico Mater Domini Università di Catanzaro
🇮🇹Catanzaro, Italy
ASL 4 Chiavarese
🇮🇹Chiavari (genova), Italy
ASST Grande Ospedale Metropolitano Niguarda
🇮🇹Milano, Italy
Seino Internal Medicine Clinic
🇯🇵Koriyama-shi, Fukushima, Japan, Japan
Manda Memorial Hospital
🇯🇵Sapporo-shi, Hokkaido, Hokkaido, Japan, Japan
Hayashi Diabetes Clinic
🇯🇵Chigasaki-shi, Kanagawa, Japan, Japan
Jinnouchi Hospital
🇯🇵Kumamoto-shi, Kumamoto, Japan, Japan
Tokyo-Eki Center-building Clinic
🇯🇵Tokyo, Japan
Fukuwa Clinic
🇯🇵Tokyo, Japan
Yokohama City University Hospital, Endocrinology, Metabolism
🇯🇵Yokohama-shi, Kanagawa, Japan
Soonchunhyang University Hospital
🇰🇷Cheonan, Chungcheongnam-do, Korea, Republic of
Korea University Ansan Hospital
🇰🇷Ansan, Gyeonggi-do, Korea, Republic of
Seoul National University Bundang Hospital_Seongnam-si
🇰🇷Seongnam-si, Korea, Republic of
Korea University Anam Hospital
🇰🇷Seoul, Korea, Republic of
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
Kangbuk Samsung Hospital
🇰🇷Seoul, Korea, Republic of
Severance Hospital, Yonsei University Health System
🇰🇷Seoul, Korea, Republic of
Asan Medical Center
🇰🇷Seoul, Korea, Republic of
Seoul Saint Mary's Hospital
🇰🇷Seoul, Korea, Republic of
Nowon Eulji Medical Center, Eulji University
🇰🇷Seoul, Korea, Republic of
Wonju Severance Christian Hospital
🇰🇷Wonju, Korea, Republic of
Hospital Universitario Dr. José Eleuterio González_Monterrey
🇲🇽Monterrey, Nuevo León, Mexico
Centro de Investigación Cardiometabólica de Aguascalientes
🇲🇽Aguascalientes, Mexico
China Medical University Hospital
🇨🇳Taichung, Taiwan
National Cheng Kung University Hospital
🇨🇳Tainan City, Taiwan
Chi Mei Medical Center
🇨🇳Tainan City, Taiwan
Taipei Medical University Hospital
🇨🇳Taipei city, Taiwan
Ankara Universitesi Ibni Sina Hastanesi
🇹🇷Ankara, Altindag, Turkey
Cukurova Universitesi Tip Fakultesi
🇹🇷Adana, Turkey
Gulhane Egitim Arastirma Hastanesi
🇹🇷Ankara, Turkey
Haseki Sultangazi
🇹🇷Istanbul, Turkey
T.C SB Goztepe Prof. Dr. Suleyman Yalcin City Hospital
🇹🇷Istanbul, Turkey
T.C. S.B. Ist Il SagMud Pendik Egitim ve Arastirma Hastanesi
🇹🇷Istanbul, Turkey
Tekirdag Namık Kemal UTF
🇹🇷Tekirdag, Turkey